TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05708183

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multiple micronutrient supplementation (MMS)
Description: Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Iron folate supplementation (IFA)
Description: IFA delivered as part of routine antenatal care, according to current policy
Study: NCT05245045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shengtaibufen Photodynamic Therapy(STBF-PDT)
Description: Shengtaibufen Photodynamic Therapy(STBF-PDT)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Red light
Description: Red light
Study: NCT04317716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fall prevention program
Description: The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure about falls and fall risk factors
Description: Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
Study: NCT04001998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: Randomized to active product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-2660
Description: Randomized to active product
Study: NCT05088538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
Study: NCT05242822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN-3248
Description: KIN-3248 will be administered orally once daily in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN-3248
Description: KIN-3248 will be administered orally once daily in 28-day cycles
Study: NCT06248112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan-Test product
Description: Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan-Reference product
Description: Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
Study: NCT06176898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulating device
Description: A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~* Six minute walking test (6MWT)~* Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires
Study: NCT04684966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Neuromuscular Electrical Stimulation
Description: Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
Study: NCT06551168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat exposure
Description: Participants will exercise at home while wearing a clothing ensemble over 19 one hour sessions. They will use validated perceptual scales to guide their effort and thermal sensation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will exercise at home over 19 one hour sessions. They will use heart rate to guide their effort. The exercise will take place in cool conditions
Study: NCT06183411

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment
Description: * Observations using two valid, observational instruments (MABC-2 and ToM test-R) that each child completes once at random.~* A demographic and developmental questionnaire is completed once by the parent/guardian at recruitment.~* Standardized questionnaires (Coordination Questionnaire For Parents (CVO), Social Responsiveness Scale second edition (SRS-2), Strengths and Difficulties Questionnaire (SDQ) and Theory of Mind Behavior Checklist (ToMBC)) are also questioned once to parent/guardian for data collection.
Study: NCT06002633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Participants will consume beverages containing alcohol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume beverages containing a very low dose of alcohol (placebo condition).
Study: NCT06014047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch vein graft
Description: Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery graft
Description: One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
Study: NCT05226234

Intervention type: DEVICE
Intervention: MRI
Description: Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
Study: NCT04910672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion.
Study: NCT05849584

Intervention type: OTHER
Intervention: Transperineal ultrasound
Description: A 2D scan will be performed of one experienced clinician. The average of 3 2D levator hiatal anteroposterior measurements will be stored. Then, a 3D/4D ultrasound examination of the pelvic floor will be performed using a Voluson S10, E8 or E10 (GE healthcare, Zipf, Austria) device with a RAB 4-8 MHz curved array transducer with the acquisition angle set at 85 degrees. Offline analysis of the ultrasound volumes will be performed using the 4D view (GE Healthcare, Austria) software, blinded to all clinical data. Hiatal anteroposterior diameter will be measured in both 2D and 3D. Hiatal area and hiatal transverse diameter will be measured in the 3D volume
Study: NCT06408363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maneuver group
Description: These maneuvers for Eustachian tube opening will be performed continuously during the compression phase of the hyperbaric chamber, every 30 minutes after reaching the desired pressurization level, and continuously during the decompression phase.
Study: NCT05388097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managed Services
Description: coordination of care and assistance with community resources (food, transportation)
Study: NCT05848453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAP5191
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAP5191
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAP5191
Description: Placebo
Study: NCT05432700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LactApp
Description: LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food.
Study: NCT05659654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: 250 mg/capsule, 2 capsules per day, for 4 weeks
Study: NCT06400004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Description: Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
Study: NCT06643169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based fall prevention program with multifactorial
Description: * Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment
Study: NCT05216926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of preventive action based on prediction model
Description: Timing of preventive action based on prediction model

Intervention type: OTHER
Group type: OTHER
Intervention: Hypoglycaemia treatment at hypoglycaemia (usual care)
Description: Hypoglycaemia treatment at hypoglycaemia (usual care)
Study: NCT06400004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
Study: NCT04375813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eRapa
Description: 0.5mg eRapa (encapsulated rapamycin) oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo capsules visually identical to eRapa oral capsules
Study: NCT05390723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communciation intervention
Description: The investigators cannot reveal the manipulated communication as this might influence participant outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communciation intervention
Description: The investigators cannot reveal the manipulated communication as this might influence participant outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communciation intervention
Description: The investigators cannot reveal the manipulated communication as this might influence participant outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communciation intervention
Description: The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
Study: NCT05640661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest II
Description: active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest II
Description: active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
Study: NCT06487533

Intervention type: DEVICE
Intervention: EmbracePlus Smartwatch
Description: The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements.

Intervention type: DEVICE
Intervention: Corti Sensor
Description: The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements.
Study: NCT05268887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham settings)
Description: Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
Study: NCT03595787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coaching and Habilitation
Description: nutritional support, adapted physical activity and coaching
Study: NCT06396377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reborn doll (Therapeutic object - OT)
Description: If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
Study: NCT06261463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAFES2
Description: The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
Study: NCT05666375

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous translumbar and transhepatic permcath
Description: For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous translumbar and transhepatic permcath
Description: For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
Study: NCT05834816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Affect Task
Description: fMRI stress task
Study: NCT05643963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary regimens
Description: Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary regimens
Description: Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
Study: NCT04963972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in Lucid Lane therapy program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care opioid education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05957757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour.
Study: NCT05518422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic, euglycemic infusion
Description: 60 minute infusion